GlassScriptPhysician profile
Sarah Villani
NPI 1770089435
$2,702.94
in general payments reported to CMS, 2019-2025
23 companies · $608 in 2025
The $608 reported for 2025 was more than what 76% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $229 · 2023: $864 · 2024: $874 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.77 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $625.54 | 2023-2024 | Jakafi |
| Eisai INC. | $236.81 | 2024-2025 | |
| Cti Biopharma Corp. | $234.79 | 2023 | Vonjo |
| Novartis Pharmaceuticals Corporation | $234.04 | 2022-2025 | |
| Janssen Biotech, INC. | $187.32 | 2024-2025 | Rybrevant, Darzalex, Tecvayli |
| Amgen INC. | $181.39 | 2021-2022 | |
| Stemline Therapeutics INC. | $152.93 | 2024-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $141.89 | 2023 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $103.29 | 2024 | Monoferric |
| Tg Therapeutics, INC. | $91.95 | 2021 | |
| Genentech USA, INC. | $90.66 | 2024-2025 | Polivy, Itovebi, Columvi |
| Astrazeneca Pharmaceuticals LP | $71.89 | 2023-2025 | Enhertu, Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $52.46 | 2024 | Welireg, Keytruda, Lynparza |
| Gilead Sciences, INC. | $52.04 | 2024-2025 | Trodelvy |
| Taiho Oncology, INC. | $39.28 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $34.54 | 2022 | |
| Genzyme Corporation | $27.98 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $27.83 | 2022 | |
| Exelixis INC. | $27.20 | 2023 | Cabometyx |
| Tempus Ai, INC | $25.51 | 2024 | |
| Beigene USA, INC. | $22.38 | 2024 | Brukinsa |
| Seagen INC. | $22.18 | 2023 | Padcev |
| Abbvie INC. | $19.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Villani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.